9 results about "Apolipoprotein B" patented technology

The utility model discloses a preparation device for apolipoprotein B, and relates to the technical field of protein preparation. The preparation device comprises a centrifugal motor, the driving end of the centrifugal motor is connected with a driving shaft which vertically extends upwards, the driving shaft is connected with a centrifugal turntable, and the centrifugal turntable is provided with a plurality of centrifugal grooves for placing test tubes; the number of the sealing cavities is the same as that of the centrifugal grooves, one ends of the sealing cavities communicate with the interiors of the centrifugal grooves, piston plates are slidably installed in the sealing cavities, and the piston plates are connected with pushing rods capable of extending into the centrifugal grooves; the air supply part is arranged on the centrifugal rotating disc and used for supplying air into the sealing cavity so as to drive the piston plate to push the jacking rod to slide towards the interior of the centrifugal groove. The test tubes placed in the centrifugal groove can be conveniently ejected out, so that the test tubes are more convenient to take and place.

The invention provides a papillary thyroid carcinoma neck lymph node metastasis risk prediction method and system based on blood indexes and TI-RADS grading, and relates to the technical field of medical data analysis. According to the method, an original data set is constructed by obtaining TI-RADS classification, the maximum diameter of nodules, the number of nodules, gender, age and conventional hematology indexes including apolipoprotein B and carcino-embryonic antigen of a patient, characteristic variables are screened by adopting LASSO regression, and an independent prediction risk factor model is established in combination with multi-factor Logistic regression. And further constructing a column graph model, carrying out performance verification through multiple statistical indexes, and deploying the model to a webpage calculator based on a shiyapp to realize convenient output of the individualized risk probability. According to the method, efficient and accurate prediction of the preoperative lymph node metastasis risk is realized, and reliable decision support can be provided for clinic.

The application discloses a kind of lipoprotein detection reagent and lipoprotein detection method, it is related to biochemical detection technical field, the lipoprotein detection reagent includes R1 reagent and R2 reagent, wherein, the R1 reagent includes anti apolipoprotein B antibody, the R2 reagent includes latex microsphere coated with lipoprotein specificity antibody. Wherein, anti apolipoprotein B antibody can preliminarily enrich target lipoprotein and form immune complex to amplify detection signal, and lipoprotein specificity antibody can specifically recognize target protein and form immune complex-lipoprotein specificity antibody-latex microsphere complex, further amplify detection signal, significantly improve the detection sensitivity of reagent.

The invention belongs to the field of gene editing, and particularly relates to a method for regulating milk fat content. The expression of genes in fatty acid and cholesterol synthesis pathways of the livers of the animals in the lactation period is specifically regulated and controlled through a gene delivery technology, the expression of liver apolipoprotein B (ApoB) and the triglyceride and total cholesterol level in blood can be remarkably reduced, then the lipid content of milk is effectively reduced, meanwhile, the food intake of the animals is reduced, and the production cost is reduced. And the milk protein content is not influenced. According to the method, milk fat components are accurately controlled through maternal liver gene editing for the first time, a new strategy is provided for breeding healthy dairy animals, and the method has wide application prospects.

The invention discloses an apolipoprotein B (ApoB) antibody related to oxidized low density lipoprotein (Ox-LDL) or a functional fragment of the apolipoprotein B antibody, and an application of the apolipoprotein B antibody and the functional fragment. The anti-Ox-ApoB antibody or the functional fragment thereof disclosed by the invention comprises a heavy chain complementarity determining region and a light chain complementarity determining region, and the antibody or the functional fragment thereof has relatively good specificity and sensitivity to Ox-ApoB, and can be used for detecting Ox-ApoB and / or Ox-LDL and used for auxiliary diagnosis of atherosclerosis by taking Ox-ApoB and / or Ox-LDL as a marker.

The utility model provides an efficient batch transfer apolipoprotein B determination kit, which relates to the technical field of reagent packaging, and comprises a storage seat, the top of the storage seat is provided with a plurality of uniformly distributed placing grooves, the top of the storage seat is fixedly provided with a vertical plate, and the outer wall of the vertical plate is provided with a plurality of uniformly distributed openings in a penetrating manner. When the reagent box is used, a worker puts the bottom of a reagent into the containing groove, then the worker rotates the grip, the grip drives the first threaded rod to rotate, the first threaded rod drives the sliding block to descend along the opening, and then the top plate is driven to descend until the bottom of the top plate makes contact with the top of the reagent; the rotating shaft drives the second threaded rod to rotate, and then drives the lifting plate to descend along the storage groove, the ejector block leaves the penetrating opening and is in contact with the clamping plates, the inclined surface of the ejector block pushes the clamping plates to move, and the two clamping plates get close to each other until the outer wall of the reagent is clamped, so that shaking during collection and storage can be prevented.

A bispecific nucleic acid molecule comprising at least two double stranded inhibitory ribonucleic acid (RNA) molecules that silence by RNA interference apolipoprotein B (ApoB) and diacylglycerol O acyltransferase 2 (DGAT2) wherein said at least two double stranded inhibitory RNA molecules are linked by a DNA linker molecule that has a melting temperature (TM) of approximately 73oC. The use of such dual siRNA constructs in treating cardiovascular related conditions including hypercholesterolemia is further claimed. [Fig. 2A]

The present invention relates to pharmaceutical composition(s) comprising particles comprising one or more compounds which are inhibitors of microsomal triglyceride transfer protein and / or apolipoprotein B (Apo B) secretion, wherein at least 50% of the particles are characterized by a volume particle fraction less than 10 μm, more preferably less than 5 μm, more preferably less than 2.5 μm. The pharmaceutical composition can be useful for the prevention and treatment of various diseases, particularly atherosclerosis and its clinical sequelae, for lowering serum lipids, and related ailments. The invention further relates to methods of treating diseases, such as hypertriglyceridemia, hyperchylomicronemia, atherosclerosis, obesity, and related conditions using the compounds. A method for decreasing apolipoprotein B (apo B) secretion is also provided.

This invention belongs to the fields of organic chemistry, medicinal chemistry, and pharmacology, specifically relating to the synthesis of lometapeptide bioelectron isosteres and their application in the preparation of therapeutic drugs for lipid-lowering diseases. A method for preparing lometapeptide bioelectron isosteres mainly includes six steps: 1) Using A and B as starting materials, under nickel catalysis and the action of phosphine ligands, a reaction occurs... endo The reaction [2+2] yielded intermediate I; 2) Intermediate I underwent intramolecular cyclization under thioxanthracene-9-one and photocatalysis to yield intermediate II; 3) Intermediate II was oxidized under alkaline potassium permanganate to yield intermediate III; 4) Intermediate III and C reacted under the action of a condensing agent to prepare amide intermediate IV; 5) Intermediate IV was debenzylated under the action of palladium on carbon and a hydrogen source to prepare amine intermediate V; 6) Intermediate V and D under alkaline conditions underwent a substitution reaction to obtain the final product, lometapetine bioelectron isostere VI. This bioelectron isostere can dose-dependently inhibit the secretion of apolipoprotein B in HepG2 cells and exhibits good kinetic solubility. This compound shows promise for development as a therapeutic drug for hypercholesterolemia-related diseases.